Raymond James Financial Services Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,571	Closed	-$102K	–	3451
2022 Q3	$102K	Buy	+17,571	New	+$110K	﹤0.01%	2992
2022 Q2	–	Sell	-15,571	Closed	-$73K	–	3500
2022 Q1	$73K	Buy	+15,571	New	+$46.4K	﹤0.01%	3149
2021 Q4	–	Sell	-72,871	Closed	-$215K	–	3515
2021 Q3	$215K	Buy	+72,871	New	+$198K	﹤0.01%	2932

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Raymond James Financial Services Advisors's CTIC Position: Q4 2022 in Review

Raymond James Financial Services Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 17,571 shares — an estimated $102K sold.

Raymond James Financial Services Advisors first reported a position in CTIC in Q3 2021 and held it in 3 quarters. The position peaked at $215K in Q3 2021. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

Raymond James Financial Services Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
Raymond James Financial Services Advisors sold 17,571 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $102K.
Raymond James Financial Services Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2021 and held it in 3 quarters.
Raymond James Financial Services Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $215K in Q3 2021.
145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.